Radius Health Inc. (NASDAQ:RDUS) Receives Consensus Rating of “Buy” from Brokerages
Radius Health Inc. (NASDAQ:RDUS) has been assigned an average recommendation of “Buy” from the eleven ratings firms that are presently covering the stock. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $63.51.
RDUS has been the topic of several recent research reports. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Canaccord Genuity set a $85.00 target price on Radius Health and gave the company a “buy” rating in a research report on Wednesday, September 28th. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $70.00 target price on shares of Radius Health in a research report on Friday, August 5th. Jefferies Group increased their target price on Radius Health from $37.00 to $46.00 and gave the company a “hold” rating in a research report on Monday, August 15th. Finally, Cowen and Company reissued a “buy” rating on shares of Radius Health in a research report on Thursday, August 4th.
Radius Health (NASDAQ:RDUS) traded down 1.17% during mid-day trading on Friday, reaching $51.47. The company had a trading volume of 219,716 shares. The firm’s market capitalization is $2.22 billion. Radius Health has a 52 week low of $24.75 and a 52 week high of $75.50. The stock’s 50-day moving average price is $55.28 and its 200 day moving average price is $42.74.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/radius-health-inc-nasdaqrdus-receives-consensus-rating-of-buy-from-brokerages.html
Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by $0.06. During the same quarter last year, the company earned ($0.61) earnings per share. On average, equities research analysts predict that Radius Health will post ($3.97) EPS for the current year.
A number of institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA raised its position in shares of Radius Health by 118.2% in the third quarter. BNP Paribas Arbitrage SA now owns 2,668 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,445 shares during the period. Macquarie Group Ltd. purchased a new position in shares of Radius Health during the second quarter worth about $747,000. Royal Bank of Canada raised its position in shares of Radius Health by 4.3% in the second quarter. Royal Bank of Canada now owns 836,118 shares of the biopharmaceutical company’s stock worth $30,729,000 after buying an additional 34,694 shares during the period. Stifel Financial Corp raised its position in shares of Radius Health by 50.7% in the second quarter. Stifel Financial Corp now owns 11,376 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 3,826 shares during the period. Finally, Fiera Capital Corp purchased a new position in shares of Radius Health during the second quarter worth about $21,097,000. Institutional investors own 99.91% of the company’s stock.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.